Skip to main content
Erschienen in:

09.05.2020 | Thoracic Oncology

The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer

verfasst von: Marcus E. Eby, MD, Christopher W. Seder, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2020

Einloggen, um Zugang zu erhalten

Auszug

Management of stage 3A non-small cell lung cancer (NSCLC) has evolved significantly during the last several decades. Despite this, a universally accepted algorithm to guide clinical decision-making remains elusive. The controversy surrounding the management of stage 3A NSCLC stems primarily from the innate heterogeneity of the disease and the varied results observed with treatment. …
Literatur
1.
Zurück zum Zitat Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987;67:1037–49.CrossRef Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am. 1987;67:1037–49.CrossRef
2.
Zurück zum Zitat Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Int Med. 1990;113:33–8.CrossRef Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Int Med. 1990;113:33–8.CrossRef
3.
Zurück zum Zitat Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst. 1995;87:198–205.CrossRef Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst. 1995;87:198–205.CrossRef
4.
Zurück zum Zitat Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621.
5.
Zurück zum Zitat Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol. 2005;23:3257–69.CrossRef Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small cell lung cancer. J Clin Oncol. 2005;23:3257–69.CrossRef
6.
Zurück zum Zitat Eberhardt WE, Albain KS, Pass H, et al. Induction treatment before surgery for non-small cell lung cancer: IASLC consensus report. Lung Cancer. 2003;42:S9–14.CrossRef Eberhardt WE, Albain KS, Pass H, et al. Induction treatment before surgery for non-small cell lung cancer: IASLC consensus report. Lung Cancer. 2003;42:S9–14.CrossRef
7.
Zurück zum Zitat Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–92.CrossRef Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880–92.CrossRef
8.
Zurück zum Zitat Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRef Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRef
9.
Zurück zum Zitat Ansari R, Tokars R, Fisher W, et al. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. Proc Am Soc Clin Oncol. 1991;10:241. Ansari R, Tokars R, Fisher W, et al. A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. Proc Am Soc Clin Oncol. 1991;10:241.
10.
Zurück zum Zitat Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–30.CrossRef Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524–30.CrossRef
11.
Zurück zum Zitat Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–23.CrossRef Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–23.CrossRef
12.
Zurück zum Zitat Dillman RO, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy versus RT alone in stage III non-small cell lung cancer: five year follow-up of CALGB 84-33. Proc Am Soc Clin Oncol. 1993;12:329. Dillman RO, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy versus RT alone in stage III non-small cell lung cancer: five year follow-up of CALGB 84-33. Proc Am Soc Clin Oncol. 1993;12:329.
13.
Zurück zum Zitat Stinchcombe TE, Fried D, Morris DE, Socinski MA. Combined-modality therapy for stage III non-small cell lung cancer. Oncologist. 2006;11:809–23.CrossRef Stinchcombe TE, Fried D, Morris DE, Socinski MA. Combined-modality therapy for stage III non-small cell lung cancer. Oncologist. 2006;11:809–23.CrossRef
14.
Zurück zum Zitat Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64.CrossRef Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–64.CrossRef
15.
Zurück zum Zitat Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.CrossRef Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst. 1994;86:673–80.CrossRef
16.
Zurück zum Zitat Veeramachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.CrossRef Veeramachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.CrossRef
17.
Zurück zum Zitat Koshy M, Fedewa SA, Malik R, Ferguson MK, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small cell lung cancer. J Thorac Oncol. 2013;8:915–22.CrossRef Koshy M, Fedewa SA, Malik R, Ferguson MK, et al. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small cell lung cancer. J Thorac Oncol. 2013;8:915–22.CrossRef
18.
Zurück zum Zitat Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med. 2017;377:1919–29.CrossRef Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. N Engl J Med. 2017;377:1919–29.CrossRef
19.
Zurück zum Zitat Chalmers AW, Patel SB, Akerley W. Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis. 2018;10:1198–200.CrossRef Chalmers AW, Patel SB, Akerley W. Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis. 2018;10:1198–200.CrossRef
Metadaten
Titel
The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer
verfasst von
Marcus E. Eby, MD
Christopher W. Seder, MD
Publikationsdatum
09.05.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08553-z

Neu im Fachgebiet Chirurgie

Hochrisiko-Spinaliom am besten mit der Mohs-Chirurgie entfernen

Die Mohs-Chirurgie ist zwar mit mehr Aufwand verbunden als die herkömmliche Exzision; für die Versorgung kutaner Hochrisiko-Plattenepithelkarzinome lohnt sich die zeitintensive Technik aber in jedem Fall. Laut einer aktuellen Studie sinkt im Vergleich das Sterberisiko.

Darmpolyp weg – Peptid-Gel gegen Nachblutungen drauf?

Das Nachblutungsrisiko nach einer endoskopischen Mukosaresektion von flachen kolorektalen und duodenalen Adenomen war in der deutschen PURPLE-Studie mit einem hämostatischen Gel nicht kleiner als ohne Prophylaxe.

Krebs-Op. besser erst nach mehrwöchigem Rauchverzicht?

Aktive Raucher haben nach onkologischen Operationen ein höheres Komplikationsrisiko als Nieraucher, aber auch als Exraucher. Damit der Rauchstopp einen Nutzen hat, darf er aber nicht zu kurz vor der Op. erfolgen, wie eine Metaanalyse nahelegt.

Periprozeduraler Myokardschaden nach NSTEMI prognostisch bedeutsam

Erleiden NSTEMI-Patienten und -Patientinnen infolge einer PCI Myokardschädigungen mit oder ohne Infarkt, erhöht das die Gesamtmortalität und das Risiko für weitere schwere Herzereignisse. Dafür sprechen zumindest Daten aus zwei italienischen Zentren.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.